Beximco Pharmaceuticals (BXP) Competitors GBX 35 -1.50 (-4.11%) (As of 12/20/2024 10:57 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines BXP vs. GROW, PRSR, DX, PINE, MGP, WPC, SOHO, LMI, ADVT, and SAGAShould you be buying Beximco Pharmaceuticals stock or one of its competitors? The main competitors of Beximco Pharmaceuticals include Molten Ventures (GROW), Prs Reit (PRSR), DX (Group) (DX), Pinewood Technologies Group (PINE), Medica Group (MGP), Witan Pacific Investment Trust PLC (WPC.L) (WPC), Triple Point Social Housing REIT (SOHO), Lonmin (LMI), AdvancedAdvT (ADVT), and Saga (SAGA). These companies are all part of the "trading" industry. Beximco Pharmaceuticals vs. Molten Ventures Prs Reit DX (Group) Pinewood Technologies Group Medica Group Witan Pacific Investment Trust PLC (WPC.L) Triple Point Social Housing REIT Lonmin AdvancedAdvT Saga Beximco Pharmaceuticals (LON:BXP) and Molten Ventures (LON:GROW) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation. Which has more volatility & risk, BXP or GROW? Beximco Pharmaceuticals has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Molten Ventures has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Which has stronger valuation and earnings, BXP or GROW? Beximco Pharmaceuticals has higher revenue and earnings than Molten Ventures. Molten Ventures is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeximco Pharmaceuticals£43.08B0.00£5.33B£0.08437.50Molten Ventures-£47.80M-12.20-£40.60M-£0.21-1,497.62 Does the MarketBeat Community prefer BXP or GROW? Molten Ventures received 146 more outperform votes than Beximco Pharmaceuticals when rated by MarketBeat users. Likewise, 77.20% of users gave Molten Ventures an outperform vote while only 64.67% of users gave Beximco Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBeximco PharmaceuticalsOutperform Votes10864.67% Underperform Votes5935.33% Molten VenturesOutperform Votes25477.20% Underperform Votes7522.80% Does the media favor BXP or GROW? In the previous week, Molten Ventures had 2 more articles in the media than Beximco Pharmaceuticals. MarketBeat recorded 2 mentions for Molten Ventures and 0 mentions for Beximco Pharmaceuticals. Molten Ventures' average media sentiment score of 1.17 beat Beximco Pharmaceuticals' score of 0.00 indicating that Molten Ventures is being referred to more favorably in the news media. Company Overall Sentiment Beximco Pharmaceuticals Neutral Molten Ventures Positive Do analysts rate BXP or GROW? Molten Ventures has a consensus price target of GBX 580, indicating a potential upside of 84.42%. Given Molten Ventures' stronger consensus rating and higher probable upside, analysts plainly believe Molten Ventures is more favorable than Beximco Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beximco Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Molten Ventures 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BXP or GROW more profitable? Beximco Pharmaceuticals has a net margin of 12.37% compared to Molten Ventures' net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 10.99% beat Molten Ventures' return on equity.Company Net Margins Return on Equity Return on Assets Beximco Pharmaceuticals12.37% 10.99% 6.97% Molten Ventures N/A -3.32%-3.46% Do insiders and institutionals have more ownership in BXP or GROW? 1.7% of Beximco Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.7% of Molten Ventures shares are owned by institutional investors. 8.6% of Molten Ventures shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryMolten Ventures beats Beximco Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Ad Stansberry Research2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisisDan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.Click here to see Dan's full warning to the public. Get Beximco Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BXP vs. The Competition Export to ExcelMetricBeximco PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£156.14M£1.15B£5.13B£1.83BDividend Yield10.27%3.04%5.08%10.56%P/E Ratio437.50131.2389.581,756.25Price / Sales0.001,962.971,116.12374,123.97Price / CashN/A10.1142.8227.80Price / Book0.003.064.772.88Net Income£5.33B£152.21M£120.15M£155.16M7 Day Performance-4.11%-0.48%-1.92%-1.90%1 Month Performance4.48%-1.32%11.47%17.32%1 Year Performance-14.63%98.66%30.52%28.55% Beximco Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BXPBeximco PharmaceuticalsN/AGBX 35-4.1%N/A-14.6%£156.14M£43.08B437.505,500News CoverageGROWMolten Ventures3.1235 of 5 starsN/AGBX 580+∞+9.7%£595.04M£-47,800,000.00-1,533.9020PRSRPrs Reit2.8892 of 5 starsGBX 106-0.2%GBX 120+13.2%+26.5%£582.21M£53.68M963.642DXDX (Group)N/AN/AN/AN/A£306.77M£471.20M1,185.0020News CoveragePINEPinewood Technologies Group2.1238 of 5 starsGBX 339.50-0.9%GBX 455+34.0%N/A£293.63M£22.62M552.425,334Gap UpHigh Trading VolumeMGPMedica GroupN/AGBX 211flatN/A+0.0%£259.85M£76.98M3,516.671,212News CoverageWPCWitan Pacific Investment Trust PLC (WPC.L)N/AGBX 397+2.3%N/AN/A£242.69M£6.74M69.65190SOHOTriple Point Social Housing REITN/AGBX 59.30-1.7%N/A-9.4%£233.33M£39.84M658.8910News CoverageLMILonminN/AN/AN/A+0.0%£213.79M£1.34B5.113,066ADVTAdvancedAdvTN/AGBX 148.40+3.1%N/A+79.3%£197.67M£15.15M14,840.00209High Trading VolumeSAGASaga1.054 of 5 starsGBX 133+7.6%GBX 154+15.8%-9.3%£189.61M£811.70M-116.603,682News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies Molten Ventures Competitors Prs Reit Competitors DX (Group) Competitors Pinewood Technologies Group Competitors Medica Group Competitors Witan Pacific Investment Trust PLC (WPC.L) Competitors Triple Point Social Housing REIT Competitors Lonmin Competitors AdvancedAdvT Competitors Saga Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:BXP) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beximco Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Beximco Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BXP Stock Alerts